Elevation Point Wealth Partners LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Elevation Point Wealth Partners LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, HoldingsChannel reports. The firm bought 895 shares of the biopharmaceutical company’s stock, valued at approximately $692,000.

Several other hedge funds have also modified their holdings of REGN. Insigneo Advisory Services LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC lifted its stake in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. MCF Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 15 shares in the last quarter. Finally, Rexford Capital Inc. grew its position in Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 15 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron to buy from hold, signaling improved confidence in the stock’s outlook. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Truist kept a buy rating and reiterated a new price target of $769, suggesting meaningful upside from current levels despite a slight target cut. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation
• Positive Sentiment: HSBC also maintained a buy rating after trimming its target to $880, reinforcing the view that analysts still see room for gains. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock and noted its favorable earnings surprise history, which may be building investor confidence ahead of the next report. Here's Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada lowered its target to $696 and kept a sector perform rating, which is a more cautious signal but still implies modest upside. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Jim Cramer’s comments that biotech could become “the hottest group in the market” added sector-wide optimism, but this was a broad industry call rather than Regeneron-specific news. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged 10b5-1 transaction, which can sometimes weigh on sentiment even though the sale was relatively small. SEC filing for director sale
• Negative Sentiment: Cantor Fitzgerald and RBC both trimmed their price targets this week, suggesting analysts have slightly more tempered expectations for near-term upside. Regeneron price target changes

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $676.23 on Wednesday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $537.45 and a fifty-two week high of $821.11. The business has a fifty day moving average of $648.64 and a 200-day moving average of $724.11. The stock has a market cap of $71.49 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the company earned $8.22 earnings per share. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.46 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Analysts Set New Price Targets

A number of research analysts have issued reports on REGN shares. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday. HSBC dropped their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Canaccord Genuity Group decreased their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $790.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.